Meeting
2014 ASCO Annual Meeting
Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.
Authors
Koichi Azuma
Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
Koichi Azuma , Hiroshige Yoshioka , Nobuyuki Yamamoto , Toshiaki Takahashi , Makoto Nishio , Nobuyuki Katakami , Myung-Ju Ahn , Tomonori Hirashima , Makoto Maemondo , Sang-We Kim , Masayoshi Noshiro , Shiro Akinaga , Keunchil Park , Chun-Ming Tsai , Tomohide Tamura , Tetsuya Mitsudomi , Kazuhiko Nakagawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01377376
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8044)
DOI
10.1200/jco.2014.32.15_suppl.8044
Abstract #
8044
Poster Bd #
225
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.
First Author: Peter Michael Ellis
Poster
2014 ASCO Annual Meeting
BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC).
First Author: Vassiliki Papadimitrakopoulou
Poster
2014 ASCO Annual Meeting
A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.
First Author: David E. Gerber